Received Jun 27, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RAB | RABIES (RABAVERT) | NOVARTIS VACCINES AND DIAGNOSTICS | 1 | Unknown | — |
The patient received only one dose of Rabavert about three months ago; Case reference number US-BN-2025-000910 is a spontaneous case initially received from pharmacist via Med Communication (reference number: USBAV25-1033) on 06-May-2025 and concerns a 42-years-old female patient. The patient's medical history and concomitant medication details were not provided. On unspecified date, reported as three months ago, the patient took first dose of RabAvert along with its constituent parts prefilled syringe, needle for injection and needle for reconstitution (batch number: unknown) at an unknown dose, route or site of administration for indication pre-exposure prophylaxis. As reported, the patient received only one dose of RabAvert about three months ago as the patient was not told about other doses needed (explicitly coded as 'incomplete course of vaccination'). At the time of initial report, it was unknown if the patient experienced any adverse event due to RabAvert. No further information was provided.; Reporter's Comments: This case concerns a 42-year-old adult female patient. On unspecified date, the patient received the first dose of RabAvert vaccine with an indication of pre-exposure prophylaxis. As reported, the patient received only one dose of RabAvert about three months ago as the patient was not told about other doses needed which is considered as incomplete course of vaccination'. At the time of initial report, it was unknown if the patient experienced any adverse event due to RabAvert. Incomplete course of vaccination is considered as listed as per company convention. The patients' medical history and concomitant medication details were not provided. Incomplete course of vaccination is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: This case concerns a 42-year-old adult female patient. On unspecified date, the patient received the first dose of RabAvert vaccine with an indication of pre-exposure prophylaxis. As reported, the patient received only one dose of RabAvert about three months ago as the patient was not told about other doses needed which is considered as incomplete course of vaccination'. At the time of initial report, it was unknown if the patient experienced any adverse event due to RabAvert. Incomplete course of vaccination is considered as listed as per company convention. The patients' medical history and concomitant medication details were not provided. Incomplete course of vaccination is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: None